NBI-1065845 (TAK-653)

NBI-1065845 (TAK-653) is being developed by Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited as part of a strategic collaboration announced in June 2020. It is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator for the treatment of major depressive disorder (MDD). Neurocrine Biosciences plans to initiate a Phase II study of NBI-1065845 in patients with inadequate response to treatment in MDD in 2021.